Appearance and prognosis of dysplasia in Barrett's esophagus

Chest Surgery Clinics of North America

Volumn 12, Issue 1, 2002, Pages 69-76

  Sampliner, Richard E ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; COLUMNAR EPITHELIUM; COMPUTER ASSISTED TOMOGRAPHY; DYSPLASIA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC SURGERY; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEALTH SURVEY; HUMAN; MORBIDITY; MORTALITY; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; RAMAN SPECTROMETRY; REVIEW; RISK FACTOR; SURVIVAL;

EID: 0036185214     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3359(03)00066-8     Document Type: Review

References (44)

1. Impact of hospital volume on operative mortality for major cancer surgery
2. Adenocarcinoma of the esophagus and Barrett's esophagus: A population based study
3. Methylene blue directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus
4. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long term omeprazole trials
5. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis
6. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
7. Practice patterns for surveillance of Barrett's esophagus in the United States
8. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high grade dysplasia
9. Management of Barrett's esophagus: A national study of practice patterns and their cost implications
10. Is H. pylori associated with specialized intestinal metaplasia of the esophagus or stomach? A prospective study of 889 patients
11. Early adenocarcinoma in Barrett's oesophagus
12. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma
13. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus
14. Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization
15. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus
16. Occult esophageal adenocarcinoma. Extent of disease and implications for effective therapy
17. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus
18. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus
19. The economic impact of the diagnosis of dysplasia in Barrett's esophagus
20. A multicenter, partially blinded, randomized study of the efficacy of photodynamic therapy using porfimer sodium for the ablation of high grade dysplasia in Barrett's esophagus: Results of 6-month follow up
21. Endoscopic fluorescence detection of high grade dysplasia in Barrett's esophagus
22. Diagnosis of specialized intestinal metaplasia by optical coherence tomography
23. p53-mutant clones and field effects in Barrett's esophagus
24. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry
25. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low and high risk patient subsets
26. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia
27. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
28. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus
29. Adenocarcinoma of the lower esophagus: A disease primarily of white men with Barrett's esophagus
30. Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophagogastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II)
31. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus
32. Partial regression of Barrett's esophagus: An inadequate endpoint
33. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole
34. Is there publication bias in the reporting of cancer risk of Barrett's esophagus?
35. Squamous islands in Barrett's esophagus: What lies underneath?
36. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression
37. Limited resection of early adenocarcinoma in Barrett's esophagus
38. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction
39. Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy
40. The diagnosis of Barrett's esophagus: Goblets, goblets, goblets
41. Omeprazole induced regression of Barrett's esophagus: A 2 year randomized, controlled double blind trial
42. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high grade dysplasia or adenocarcinoma
43. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia
44. p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma